Jose María Soler

Contact information	• Av Medrano 134 floor 6 Caba. Bs As. Argentina. Zip Cod.l C1179AAB . • phone +54 11 4983 1589 . phone +54 9 11 44138877 • Email: drjosemsoler@gmail.com
Education	• Medical Doctor, National University of Tucumán 1984. • Specialist in cardiology, University of Bs As 1991 • Specialist in echocardiography, Medical College of Bs As 1992 • Specialist in hypertension. Favaloro University 2001 • Medical Researcher, Ponclifa Conicet. 2008. • Good clinical practices Quintiles. 2012 • Provision 6677/10 ANMAT, Novo Nordisk 2015 • Good Clinical Practice Brookwood International Academy, 2015 • Good clinical practices, Eli Lilly Jun 2017. • Data systems for research: Medidata, Inform, Rave, Oracle. • Good Clinical Practice, The Global Healt Network, Oct 2021. • Diploma in Good Practices in Biomedical Research. University of San Pablo.Tucumán. August 2020 to July 2021 (238 hours).
Current employment information	• **Investigaciones Médicas IMOBA SRL** Av Medrano 134 floor 6 CABA Physician coordinator and principal investigator in the area of cardiology from 2009 to the present. • **Sana**torio Mater Dei

	Chief of the arterial hypertension service, from January 2009 to the present. • **Hospital Municipal Zubizarreta** Chief of the arterial hypertension service, from 2003 to the present
License	**M.N 69064**
Clinical studies in the last 5 years	➢ 28431754DNE3001 CREDENCET Multicenter, randomized, double-blind, event-motivated, placebo-controlled study of the effects of canaglifozin on renal and cardiovascular outcomes in subjects with type II diabetes and diabetic nephropathy. Phase III. From 2015 to 2019. Deputy InvestigatorJanssen. ➢ GSK716155 HARMONY: Long-term, randomized, double-blind, placebo-controlled study to determine the effect of biglutide in addition to standard blood glucose-lowering therapies on major cardiovascular events in patients with type 2 diabetes. From 2016 to 2018 Phase III. Glaxo.Sub Investigator. ➢ CLCZ696D2301: Multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of CLCZ696 compared with valsartan, on morbidity and mortality in patients with heart failure (NYHA class II-IV) with preserved ejection fraction. clinical trials, phase III, From 2016 to 2018, Novartis. Principal investigator. ➢ NN9068-4228 DUALTMVIII: Clinical study comparing long-term glycemic control of insulin degludec / liraglutide (IDegLira) versus insulin glargine therapy in subjects with 104-week duration of type 2 diabetes mellitus. From 2016 to 2018. Phase III. Novo Nordisk. Sub ➢ NN9924-4222 PIONEER 3: Long-term efficacy and safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes. Phase III. From 2016 to 2018. Sub Investigator. Novo Nordisk. ➢ I8B-MC-ITRN Prospective, double-blind, randomized study of LY900014 compared with insulin Lispro in combination with insulin Glargine or insulin Degludec in adults with type 2 diabetes PRONTO-T2D. From 2016 to 2019. Phase III. Eli Lilly. Sub Investigator. ➢ ¬ I8B-MC-ITRM Prospective, double-blind, randomized study of LY900014 compared with Lispro insulin with an open-label treatment group with postprandial LY900014 in combination with insulin Glargine or insulin Degludec in adults with type 1 diabetes PRONTO-T1D. From 2016 to 2019. Phase III. Eli Lilly. Sub Investigator. ➢ CLCZ696D2301 Estudio multicéntrico, aleatorizado, doble ciego, de grupos

paralelos, con control activo, para evaluar la eficacia y la seguridad de LCZ696, en comparación con valsartán, sobre la morbilidad y la mortalidad en participantes con insuficiencia cardiaca (Clase II-IV de la NYHA) y fracción de eyección conservada. Desde 2017 hasta la actualidad. Fase 3. Novartis. Investigador principal.

- LIK066 Multicenter, randomized, double-blind, parallel-group, dose-finding study to evaluate the effect of 3 doses of LIK066 compared to placebo or pagliflozin in patients with type 2 diabetes mellitus with heart failure. From 2016 to 2018. Phase III. Novartis. Principal investigator.

- EFC14828 –AMPLITUDE-O - Multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of efpeglenatide on cardiovascular outcomes in patients with type 2 diabetes who are at high risk for cardiovascular disease. Sanofi Aventis. Phase III. From 2017 to Jun 2021. Sub Investigator.

- EFC14875- SCORED: Multicenter, randomized, double-blind, placebo-controlled study in parallel groups, to demonstrate the effects of zotagliphozin on cardiovascular and renal events in patients with type II diabetes, cardiovascular risk factors and moderate renal failure. Phase III. Sanofi Aventis. From 2017 to april 2021. Sub Investigator.

- ¬ Protocol H9X-MC-GBGL "A randomized, double-blind, parallel-arm study to study the efficacy and safety of investigational doses of Dulaglutide when added to Metformin in patients with type 2 diabetes mellitus." From 2018 to December 2019. Phase III. Sub Investigator. Eli Lilly.

- 1002-043 (CLEAR), entitled “Randomized, double-blind, placebo-controlled study to evaluate the effects of bempedoic acid (ETC-1002) on the occurrence of cardiovascular events in patients with disease) cardiovascular or with high risk of developing it , which do not tolerate statins ”. Phase III. Clixar. Coordinator of clinical studies. From 2018 to the present. Principal Investigator.

- K-877-302 Prominent Pemafibrate to reduce cardiovascular outcomes by lowering triglycerides in patients with diabetes. From 2017 to the present. Phase III. Quintiles. Sub Investigator.

- I8F-MC-GPGM Efficacy and safety of Ly3298176 once a week vs insulin glargine in patients with type 2 diabetes and high cardiovascular risk. From March 2018 to July 2021. Phase III. Eli Lilly. Sub investigator.

	➢ I8F-MC-GPGH: Phase 3 open-label, randomized study comparing the effect of LY3298176 vs titrated insulin Degludec on the glycemic control of pts. with type 2 diabetes. Eli Lilly. From July 2018 to April 2021. Phase III. Eli Lilly. Sub Investigator. ➢ I8F-MC-GPGL: Randomized, open-label, phase 3 trial, comparing the efficiency and safety of Tirzepatide vs Semaglutide once a week as an add-on therapy to metformin in patients with type 2 DBT. Eli Lilly. From July 2019 to May 2021. Phase III. Eli Lilly. Sub Investigator.

Signature: Date: